This document is an FCC Authorization letter from Neuspera Medical Inc. It formally authorizes Bay Area Compliance Laboratories Corporation to act as Neuspera's agent in all matters relating to applications for equipment authorization with the Federal Communications Commission (FCC). This includes the signing of all necessary documents.
The letter confirms that Neuspera Medical Inc. is not subject to any denial of federal benefits, including FCC benefits, as per Section 5301 of the Anti-Drug Abuse Act of 1988. The authorization remains valid until further written notice is provided by Neuspera Medical Inc.
The document is signed by Dr. Alexander Yeh, CTO, VP R&D of Neuspera Medical Inc. and includes contact information and the company's address. The letter is dated 12/30/2024.
Array
(
[0] => Array
(
[url_sha] => 07f9180f6b826dd12451044590203bec669d4c978412a3574ee80db7d09787a9
[source] => fccid
[url] => https://apps.fcc.gov/eas/GetApplicationAttachment.html?id=8308084
[href_text] => FCC Agent Authorization Letter
[href_description] => Neuspera Medical Inc. WT-002 Neurostimulator Powering Device 2BMNE-WT-002 2BMNEWT002 wt 002
[http_status] => 200
[http_lastmod] => 0000-00-00 00:00:00
[http_contenttype] =>
[http_filename] => GetApplicationAttachment.html?id=8308084
[http_size] => 33641
[file_sha256] => 39a9b8948797aa2a41b264a52be5ab7416dfeb553279875e996581ee9d5546a7
[domain] => document.fccid
)
)
Array
(
[file_sha256] => 39a9b8948797aa2a41b264a52be5ab7416dfeb553279875e996581ee9d5546a7
[cleanFccId] => 2BMNEWT002
[title] => FCC Authorization: Neuspera Medical Inc. Agent Approval
[description] => Neuspera Medical Inc. authorizes Bay Area Compliance Laboratories Corporation to act on its behalf for FCC equipment authorization.
[brand_name] => Neuspera
[keywords] => []
[intro] =>
This document is an FCC Authorization letter from Neuspera Medical Inc. It formally authorizes Bay Area Compliance Laboratories Corporation to act as Neuspera's agent in all matters relating to applications for equipment authorization with the Federal Communications Commission (FCC). This includes the signing of all necessary documents.
The letter confirms that Neuspera Medical Inc. is not subject to any denial of federal benefits, including FCC benefits, as per Section 5301 of the Anti-Drug Abuse Act of 1988. The authorization remains valid until further written notice is provided by Neuspera Medical Inc.
The document is signed by Dr. Alexander Yeh, CTO, VP R&D of Neuspera Medical Inc. and includes contact information and the company's address. The letter is dated 12/30/2024.
)
Array
(
[0] => Array
(
[id] => 8308084
[file_sha256] =>
[applicationId] => r4BN3DPg6fQa6D9VGAMKkg==
[description] => FCC Agent Authorization Letter
[shortTermConfidential] => No
[permanentConfidential] => No
[supercede] => No
[exhibitType] => Cover Letter(s)
[fileType] => Adobe Acrobat PDF
[displayType] => pdf
[fileSize] => 33641
[submissionDate] => 2025-05-20 00:00:00
[dateAvailable] => 2025-05-20 00:00:00
[creationDate] =>
[producer] =>
[modDate] =>
[title] =>
[creator] =>
[author] =>
[pages] =>
[realSize] =>
[html] => 0
[png] => 0
[txt] => 0
[version] => 1
[source] => 0
[fccId] => 2BMNE-WT-002
[cleanFccId] => 2BMNEWT002
[exif] => 0
)
)